Emosis Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 21

Employees
  • Latest Deal Type
  • PE Growth

  • Financing Rounds
  • 3

Emosis General Information

Description

Operator of a med tech company intended to address the largely unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases. The company specializes in the development and commercialization of in vitro diagnostic tests for hemostasis abnormalities that cause hemorrhagic or thromboembolic manifestations and also aims to inform physician medical decisions with respect to bleeding or clotting events in a broad range of clinical settings, enabling patients to get neurovascular diseases, cancer, pregnancy and pharmacological and non-pharmacological therapy management.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Devices and Supplies
Primary Office
  • 11 rue de l'Industrie
  • 67400 Illkirch-Graffenstaden
  • France
+33 03 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Emosis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Emosis‘s full profile, request access.

Request a free trial

Emosis Patents

Emosis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210011035-A1 A rapid, on-demand heparin-induced thrombocytopenia functional assay Pending 29-Mar-2017 00000000000
EP-3602070-A1 A rapid, on-demand heparin-induced thrombocytopenia functional assay Active 29-Mar-2017 00000000000
EP-3602070-B1 A rapid, on-demand heparin-induced thrombocytopenia functional assay Active 29-Mar-2017 000000000
CA-3057743-A1 A rapid, on-demand heparin-induced thrombocytopenia functional assay Pending 29-Mar-2017 00000000000
AU-2018242607-A1 A rapid, on-demand heparin-induced thrombocytopenia functional assay Pending 29-Mar-2017 G01N33/6893
To view Emosis’s complete patent history, request access »

Emosis Executive Team (5)

Name Title Board Seat Contact Info
Frédéric Allemand MD Co-Founder & Chief Executive Officer
Florian George Ph.D Chief Financial Officer
Jean Amiral Ph.D Chief Technology Officer
Aaron Tomer Chief Scientific Officer & Co-Founder
Anh N'Guyen Ph.D Chairman & Co-Founder
To view Emosis’s complete executive team members history, request access »

Emosis Board Members (7)

Name Representing Role Since
000 0'00000 00.0 Self Chairman & Co-Founder 000 0000
000000 0000é Self Board Observer 000 0000
0000000 0000000-000000 00.0 Self Board Member 000 0000
0000-0000ç000 000 Capital Grand Est Board Member 000 0000
0000-0000 0000 Emosis Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Emosis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Emosis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Emosis‘s full profile, request access.

Request a free trial